Chong Kun Dang partners with Abclon for blood cancer drugs
Chong Kun Dang partners with Abclon to accelerate drug development and enter blood cancer treatment market. They will collaborate on CAR-T therapy AT101 for lymphoma.
Will Kymriah's dominance in Korean CAR-T market change?
Gilead's Yescarta seeks approval in Korea. CuroCell and AbClon are advancing their CAR-T therapies, potentially disrupting Novartis' Kymriah's dominance in the Korean market.
AppClon targets Europe and Middle East with CAR-T therapy
AppClon signs contract with Turkey's TCT for CAR-T cell therapy AT101, targeting blood cancer market in Europe and Middle East. AT101 shows high efficacy and safety in clinical trials.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.